Marsh, Alexandra M. R. published the artcileHistone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches, Product Details of C10H18O4, the publication is Clinical Investigation (London, United Kingdom) (2013), 3(6), 571-594, database is CAplus.
A review. Histone deacetylases play an important role in multiple processes, including gene expression, proliferation, apoptosis, cytoskeletal organization, migration and angiogenesis. Histone deacetylase inhibitors are able to induce cell death and growth arrest as targeted anticancer agents. While only two, vorinostat and romidepsin, are licensed in oncol., several have reached Phase III trials and many more are in Phase I and II. In addition to this, multiple novel drugs, including more targeted agents, are emerging from preclin. studies. This paper examines the outcomes of recent clin. trials in 11 key histone deacetylase inhibitors, both as monotherapy and in combination with other antitumor drugs. An overview of the advantages and disadvantages between the different classes and individual drugs is discussed, as well as a brief outlook on the future developments in the field.
Clinical Investigation (London, United Kingdom) published new progress about 122110-53-6. 122110-53-6 belongs to esters-buliding-blocks, auxiliary class Aliphatic hydrocarbon chain,Ester,Inhibitor, name is (Pivaloyloxy)methyl butyrate, and the molecular formula is C10H18O4, Product Details of C10H18O4.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics